BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8187796)

  • 1. Comparative activity of the new fluoroquinolone Bay y3118 against 177 penicillin susceptible and resistant pneumococci.
    Spangler SK; Jacobs MR; Appelbaum PC
    Eur J Clin Microbiol Infect Dis; 1993 Dec; 12(12):965-7. PubMed ID: 8187796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1992 Apr; 36(4):856-9. PubMed ID: 1323956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424 and RP 67829.
    Spangler SK; Jacobs MR; Pankuch GA; Appelbaum PC
    J Antimicrob Chemother; 1993 Feb; 31(2):273-80. PubMed ID: 8463172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
    Hoellman DB; Lin G; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1999 May; 43(5):645-9. PubMed ID: 10382885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of BAY 12-8039, a new fluoroquinolone.
    Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
    Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
    Souli M; Wennersten CB; Eliopoulos GM
    Int J Antimicrob Agents; 1998 Apr; 10(1):23-30. PubMed ID: 9624540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis.
    Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA
    Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.
    Visalli MA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Feb; 40(2):362-6. PubMed ID: 8834881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
    Klugman KP; Capper T
    J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of 90 penicillin-susceptible and -resistant pneumococci to penicillin G, amoxicillin, amoxicillin/clavulanate, cefaclor, cefuroxime, cefpodoxime, cefixime and imipenem.
    Hupková H; Trupl J
    Folia Microbiol (Praha); 1998; 43(1):68-70. PubMed ID: 9569631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
    Reinert RR; Lütticken R; Lemperle M; Bryskier A
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of penicillin-susceptible and -resistant pneumococci to CFC-222, a new fluoroquinolone.
    Kim JH; Kang JA; Lee Y; Lee KH; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Oct; 42(4):527-30. PubMed ID: 9818754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.
    Spangler SK; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2902-4. PubMed ID: 7695280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
    George J; Morrissey I
    J Antimicrob Chemother; 1997 Jun; 39(6):719-23. PubMed ID: 9222040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia.
    Urbásková P; Trupl J; Hupková H; Appelbaum PC; Jacobs MR
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):686-8. PubMed ID: 8894582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of penicillin-sensitive and -resistant strains of Streptococcus pneumoniae to new antimicrobial agents, including daptomycin, teicoplanin, cefpodoxime and quinolones.
    Appelbaum PC; Spangler SK; Crotty E; Jacobs MR
    J Antimicrob Chemother; 1989 Apr; 23(4):509-16. PubMed ID: 2545656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.